Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.